Furthermore, our objectives were extended to encompass the synthesis of pteridine derivatives, since pteridine-based compounds have shown promising anticancer results against various cancer types in preclinical studies, as well as in early clinical trials for the treatment of hematological malignancies as dual inhibitors of BRD4 and PLK1 [32,33,34]. This evidence concerns the gene PLK1 and cancer.